How do we treat #VEXAS – UBA1 mutation
Large multicenter cohort – 110 pts, 99% M
Confirms the benefit of JAKi and tocilizumab
Others not so much
@RheumNow #ACR23 #ACRBest
#abstL03 https://t.co/tRjO31IHiD
StillsNow
An educational site for Physicians and Patients with Still's disease (systemic juvenile idiopathic arthritis), periodic fever syndromes and autoinflammatory diseases
